Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
IL-10 (human):Fc (LALA-PG)-KIH (human) (rec.)
As low as
440
CHF
CHF 440.00
In stock
Only %1 left
AG-40B-0265-C05050 µgCHF 440.00
Figure 1: Protein structure of IL-10 (human):Fc (LALA-PG)-KIH (human) (rec.) (Prod. No. AG-40B-0265).
| Product Details | |
|---|---|
| Synonyms | InVivoKine™; IL-10 (human):Fc (LALA-PG) Knobs-into-Holes (human) (rec.); Interleukin-10; Cytokine Synthesis Inhibitory Factor; CSIF |
| Product Type | Protein |
| Properties | |
| Source/Host | HEK 293 cells. Produced using animal component-free medium. |
| Sequence |
Human IL-10 (aa 19 - 178) is fused at the C-terminus to the Fc portions of human IgG1 (LALA-PG) (Knobs-into-Holes technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)). |
| Crossreactivity | Human |
| MW | ~ 53 kDa and ~ 53kDa (SDS-PAGE) |
| Purity | ≥95% (SDS-PAGE) |
| Endotoxin Content | <0.0007 EU/μg protein (LAL test). |
| Concentration | After reconstitution: 1mg/ml |
| Reconstitution | Reconstitute with 50μl endotoxin-free water. |
| Accession Number | P22301 |
| Formulation | Lyophilized. Contains PBS. |
| Protein Negative Control |
Fc (LALA-PG)-KIH (human) IgG1 Control (rec.) (Prod. No. AG-35B-0018) |
| Other Product Data |
Uniprot link P22301: IL-10 (human) |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0.1% BSA should be used for further dilutions. |
| Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Interleukin-10 (IL-10) is a homodimeric cytokine. Its functional form consists of two identical monomers, each composed of approximately 160 amino acids. These monomers are arranged in a noncovalent dimer, stabilized by hydrophobic and electrostatic interactions. This dimeric structure is essential for IL-10's ability to bind its receptor complex, which includes IL-10 receptor α (IL-10R1) and IL-10 receptor β (IL-10R2), to mediate its anti-inflammatory and immunoregulatory functions.
IL-10 is a cytokine with multiple, pleiotropic, effects in immunoregulation and inflammation. It downregulates the expression of Th1 cytokines, MHC class II antigens, and co-stimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. IL-10 can block NF-κB activity, and is involved in the regulation of the JAK-STAT signaling pathway.
IL-10 is an immune suppressive cytokine as it plays an important regulatory role in limiting excessive immune response to inflammation and in protection against autoimmune diseases. Through the downregulation of major histocompatibility complex (MHC-II), IL-10 blunts dendritic cell (DC) response to antigen stimulation, thus inhibiting the production of several stimulatory cytokines. IL-10 can enhance the survival of B cells and cytotoxic T cells, aiding in the immune response to certain viral infections. IL-10 also inhibits CD4+ T cells’ proliferation and function, thus contributing to an immunosuppressive tumor microenvironment.
The protein IL-10 (human):Fc (LALA-PG)-KIH (human) (rec.) is produced by using two different vectors, one encoding for the IL-10 (human):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 53 kDa) and one encoding for the IL-10 (human):Fc (LALA-PG) Holes sequence (synthesizing a protein of 53kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein IL-10 (human):Fc (LALA-PG)-KIH (human) (rec.). The LALA-PG mutations inhibit binding to FcγRs and C1q while FcRn binding and Fc stability remain unaffected.
InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.
Related Products
